CCDR: Volume 51-8, August 2025: Antiviral Therapy

Table of contents

Advisory Committee Statement

Summary of the National Advisory Committee on Immunization (NACI) statement on the prevention of respiratory syncytial virus (RSV) in older adults
A Killikelly, W Siu, EM Abrams, N Brousseau on behalf of the National Advisory Committee on Immunization (NACI)

Surveillance

Evaluation of a real-time hospital surveillance system for respiratory syncytial virus, Ontario, Canada, 2022–2023
M Murti, A Sarnocinska, M Alavinejad, A Kerem, K Malikov, K Brown, T Fitzpatrick, M Hillmer

Qualitative Study

Implementation of the COVID-19 antiviral therapy Nirmatrelvir/Ritonavir (Paxlovid^TM) across Canada in 2022: A qualitative analysis of key facilitating factors and challenges
A Workneh, C Thieba, N Sicard

Commentary

Effectiveness of the four-component protein-based meningococcal vaccine against Neisseria gonorrhoeae infections: Mounting evidence and public health implications for Canada
P De Wals, Y-G Bui, M Desjardins

Rapid Communication

Safety monitoring of Imvamune vaccine during the 2022 mpox outbreak in Canada
C Wells, Y Xu, A Weeks, A Shaw, S Ogunnaike-Cooke

• Next page